Evidence map›Paper›PMID 31209595›Full record

Trial reportCancer causes & control : CCC2019

Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.

P T T Kinnunen, T J Murtola, K Talala, K Taari, T L J Tammela, A Auvinen

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Cancer causes & control : CCC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

P T T KinnunenSchool of Medicine, University of Tampere, Tampere, Finland. Kinnunen.Pete.T@student.uta.fi.ORCID http://orcid.org/0000-0003-1432-9272
T J MurtolaSchool of Medicine, University of Tampere, Tampere, Finland.
K TalalaFinnish Cancer Registry, Helsinki, Finland.
K TaariDepartment of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
T L J TammelaSchool of Medicine, University of Tampere, Tampere, Finland.
A AuvinenDepartment of Epidemiology, University of Tampere, Tampere, Finland.
Tampere University · FIFinnish Cancer Registry · FITampere University of Applied Sciences · FIUniversity of Helsinki · FI

Funding

Academy of Finland 132385Academy of Finland 260 931Pirkanmaa Hospital District 150640
6 · The paper itself

Abstract

purposeAnticoagulants may reduce mortality of cancer patients, though the evidence remains controversial. We studied the association between different anticoagulants and cancer death.

methodsAll anticoagulant use during 1995-2015 was analyzed among 75,336 men in the Finnish Randomized Study of Screening for Prostate Cancer. Men with prevalent cancer were excluded. Multivariable Cox regression was performed to compare risk of death from any cancer and disease-specific death from 9 specific cancer types between (1) anticoagulant users overall and (2) warfarin users compared to anticoagulant non-users and (3) warfarin or (4) low-molecular-weight heparins (LMWH) compared to users of other anticoagulants. Medication use was analyzed as time-dependent variable to minimize immortal time bias. 1-, 2- and 3-year lag-time analyses were performed.

resultsDuring a median follow-up of 17.2 years, a total of 27,233 men died of whom 8033 with cancer as the primary cause of death. In total, 32,628 men (43%) used anticoagulants. Any anticoagulant use was associated with an increased risk of cancer death (HR = 2.50, 95% CI 2.37-2.64) compared to non-users. Risk was similar independent of the amount, duration, or intensity of use. The risk increase was observed both among warfarin and LMWH users, although not as strong in warfarin users. Additionally, cancer-specific risks of death were similar to overall cancer mortality in all anticoagulant categories.

conclusionOur study does not support reduced cancer mortality among anticoagulant users. Future studies on drug use and cancer mortality should be adjusted for anticoagulants as they are associated with significantly higher risk of cancer death.

Indexed as

Prostatic NeoplasmsAgedAnticoagulantsEarly Detection of CancerFinlandHeparin, Low-Molecular-WeightHumansMaleMiddle AgedRisk FactorsWarfarinAnticoagulantsHeparin, Low-Molecular-WeightWarfarinAnticoagulantCancer mortalityCohortLow-molecular weight heparinsWarfarin

Identifiers

PMID31209595
OpenAlexW2951690263

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.